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Methods
Patient selection criteria
Patients with follicular lymphoma (FL) were eligible for enrollment if aged ≥18 years with histologically confirmed, previously untreated, CD20-positive disease (histologic grades 1-3a) of stages III or IV (or stage II with bulky disease, i.e., largest tumor diameter ≥7 cm), with at least 1 bidimensionally measurable lesion, Eastern Cooperative Oncology Group (ECOG) performance status 0-2, adequate hematologic function, and requiring treatment according to 'Groupe d'Étude des Lymphomes Folliculaires' (GELF) criteria. 10 The time between histologic confirmation of FL and randomization could not exceed 12 months. The primary study endpoint was investigator-assessed PFS, defined as time from randomization to PD, relapse, or death from any cause.
Treatments
Patients were randomized 1:1 to induction therapy with intravenous (i.v.) infusions of G 1000 mg (days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles) or R 375 mg/m 2 (day 1 of each cycle) plus chemotherapy for 6 or 8 cycles depending on the selected chemotherapy. Randomization was stratified by chemotherapy regimen, Follicular Lymphoma International Prognostic Index (FLIPI), 2 and geographic region. 1 of 3 chemotherapy regimens (cyclophosphamide, vincristine, doxorubicin, and prednisone [CHOP] ; cyclophosphamide, vincristine, and prednisone [CVP]; or bendamustine) was selected upfront by each center and standard doses were used; all patients at a given center received the same regimen.
Patients with a complete or partial response at the end of induction (EOI) received maintenance therapy with the same antibody as used during induction, i.e., G 1000 mg or R 375 mg/m 2 , every 2 months for 2 years or until disease progression (PD) if earlier; no crossover was allowed.
Disease progression and transformation
Response and PD were assessed using the revised response criteria for malignant lymphoma. 3 When investigators suspected PD, a full tumor assessment was performed, including a computed tomography (CT) scan (limited to areas of prior involvement if required by local authorities). For tissue samples taken at progression or suspected transformation, information from local pathology was collected. Patients with PD were followed every 6 months for OS and new antilymphoma treatment until the end of the study. 
Alternative imaging methods
Results
Survival and mortality by chemotherapy regimen, FLIPI risk category and treatment arm
Fewer POD24 events occurred in G-chemo versus R-chemo patients across all 3 chemotherapy regimen groups, with the highest rate of events observed in patients treated with CVP (cumulative incidence: bendamustine 7.4% versus 16.1%; CHOP 12.5% versus 16.9%; CVP 16.9 versus 26.9%, respectively;Online Supplementary Table S5 ). Average risk reduction was 56.2% (95% CI: 28.9-73.0%), 27.2% (95% CI: -24.4-57.4%) and 45.5% (-27.7-75.4%) for the bendamustine, CHOP and CVP treatment groups, respectively. Excluding those patients treated with CVP from the analysis, fewer POD24 events were observed in G-chemo patients versus R-chemo patients (cumulative incidence 9.3% versus 16.4%, respectively), with an average risk reduction of 45.7% (95% CI: 22.4-65.2%). 2-year post-progression survival was broadly similar between the G-and R-chemo treatment arms for patients in the bendamustine (0.54 versus 0.60, respectively) and CHOP (0.76 versus 0.74, respectively) groups. Differences were observed in the CVP group (2-year post-progression survival 0.90 versus 0.61 for the G-versus Rchemo arm, respectively), although patient numbers were small in this subgroup. 
Histologic transformation
During the first 24 months, G-chemo reduced the risk of disease transformation by 43% relative to R-chemo (95% CI: −19.8-72.8%; P=0.1330, Gray's test for equality), a similar proportional reduction to that seen for the risk of POD24 events. The cumulative incidence of transformation, in which POD24 and death without prior progression or transformation are considered as competing events, is shown in Online Supplementary Figure S4 . The overall cumulative incidence rates for transformation were 1.9% (G-chemo) and 3.3% (R-chemo). Lymphoma types at transformation are listed in Online Supplementary Table S7. NALT Some differences were seen in the type of NALT received after PD according to the timing of POD. POD24 patients were more likely to be treated with immunochemotherapy or anti-CD20 monotherapy, whereas noPOD24 patients were more likely to receive radiotherapy or other therapy; however, in the POD24 and noPOD24 groups, there were no major differences between treatment arms in the type of NALT received after PD, whenever this occurred (see Online Supplementary   Table S8 ). In patients with disease transformation 2 (4) 0 2 (1) 0 0 0
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Deaths unrelated to PD 4 (7) 12 (12) 16 (10) 9 (2) 6 (1) 15 (2) In patients with disease transformation 0 0 0 0 0 0
Abbreviations: G-chemo: obinutuzumab plus chemotherapy; PD: progressive disease; POD: progressive disease or death due to progressive disease; Rchemo: rituximab plus chemotherapy. a NOTE. At the clinical cut-off date, 95 patients had died; 23 of these patients (G-chemo, n=14; R-chemo, n=9) are not shown above as they had insufficient response follow-up. Abbreviations: CI: confidence interval; G-chemo: obinutuzumab plus chemotherapy; POD: progressive disease or death due to progressive disease; Rchemo: rituximab plus chemotherapy. a POD events occurring later than 24 months after randomization. b 1 patient died after a late POD event; this patient was randomized to G-chemo but received no study treatment (new anti-lymphoma treatment was started 1 week after randomization). There was no disease follow-up but after 3 years the patient had died, reportedly following disease progression (exact time of POD event unknown). This patient is also included in the numerator for patients with no prior POD24 event. c All patients started in the noPOD24 group at randomization and moved to the POD24 group at the time of the POD24 event. Abbreviations: CI: confidence interval; FLIPI: Follicular Lymphoma International Prognostic Index; G-chemo: obinutuzumab plus chemotherapy; POD: progressive disease or death; PPS: post-progression survival, R-chemo: rituximab plus chemotherapy. Abbreviations: CI: confidence interval; PD: progressive disease; POD: progressive disease or death due to progressive disease. a Calculated as time between a POD24 event and the earlier of death or the end of follow-up. b All patients started in the noPOD24 group at randomization, and moved to POD24 group at the time of the POD24 event. c Calculated as time between randomization and the earliest of POD24 event, death, or the end of follow-up.
